BPC-157 for Wound Healing: Off-Label Dosing Protocol, Evidence, and Safety

What Is BPC-157 and Why Is It Used Off-Label?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a 15-amino-acid chain isolated from a larger protein found in human gastric juice. It has no FDA approval for any medical condition. No regulatory agency worldwide has granted marketing authorization for BPC-157 as a pharmaceutical product.

Origin and Pharmacology

The peptide was first characterized in the early 1990s by researchers at the University of Zagreb. Its amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a partial sequence of the naturally occurring body protection compound found in gastric secretions 1. In cell culture and animal models, BPC-157 upregulates vascular endothelial growth factor (VEGF), stimulates nitric oxide synthesis through the eNOS pathway, and promotes fibroblast migration to wound beds 2.

Why Clinicians Consider It

Despite the absence of human trial data, BPC-157 has gained traction in integrative and regenerative medicine clinics. Practitioners cite the peptide's broad preclinical profile across tissue types: skin, tendon, ligament, muscle, and GI mucosa. The wound-healing interest specifically stems from rodent studies showing dramatically faster closure of full-thickness skin wounds, a finding replicated across multiple independent laboratory groups 3.

The gap between animal evidence and clinical adoption is wide. Patients should understand that "off-label" here does not mean the drug is approved for something else and repurposed. BPC-157 is not approved for anything. Every human use is investigational.

Preclinical Evidence for Wound Healing

The wound-healing data for BPC-157 comes exclusively from animal and in-vitro studies. No phase I, II, or III human trial has been completed or registered on ClinicalTrials.gov for wound healing as of May 2026. This places the evidence at GRADE Very Low certainty for clinical decision-making.

Rodent Full-Thickness Wound Models

In a 2018 study published in the Journal of Physiology and Pharmacology, BPC-157 administered intraperitoneally at 10 mcg/kg accelerated full-thickness cutaneous wound closure in rats by approximately 57% compared with saline controls at day 7 (p <0.01) 2. Histological analysis showed increased granulation tissue thickness, higher capillary density, and greater collagen type I deposition. A separate group at the University of Zagreb demonstrated similar findings in diabetic rat models, where wound healing is typically impaired, suggesting the peptide may partially overcome the angiogenic deficit seen in hyperglycemic tissue 4.

Tendon, Ligament, and Muscle Repair

BPC-157's wound-healing effects extend beyond skin in animal models. Studies show accelerated repair in transected Achilles tendons (rats), medial collateral ligament injuries (rats), and crushed muscle tissue (mice) 5. The proposed mechanism involves upregulation of growth hormone receptor expression in fibroblasts, increased VEGF-mediated angiogenesis, and modulation of the NO system through eNOS and iNOS pathways 6.

What the Animal Data Does Not Tell Us

Rodent skin heals by contraction. Human skin heals primarily by re-epithelialization. This fundamental biological difference means that faster wound closure in a rat does not predict faster closure in a human. Dose translation from animal to human using allometric scaling (the FDA body surface area method) provides a rough estimate, but pharmacokinetic parameters like bioavailability, half-life, and tissue distribution of BPC-157 in humans remain unmeasured.

Off-Label Dosing Protocols

The dosing protocols below reflect what is reported in clinical practice surveys, peptide prescribing guides from regenerative medicine organizations, and conference proceedings. They are not derived from controlled human trials.

Subcutaneous Injection Protocol

Most practitioners who prescribe BPC-157 for wound healing use subcutaneous injection as the primary route. The rationale is local tissue delivery near the wound site.

Commonly reported protocol:

• Dose: 200 to 500 mcg per injection
• Frequency: Once daily, sometimes split into twice daily (100 to 250 mcg per dose)
• Injection site: Subcutaneously within 2 to 4 cm of the wound or injury
• Cycle length: 4 to 8 weeks, followed by a 2- to 4-week washout
• Reconstitution: Lyophilized BPC-157 is reconstituted with bacteriostatic water; typical vials contain 5 mg requiring refrigeration after reconstitution

The 250 mcg twice-daily regimen is the most frequently cited in integrative medicine literature and peptide therapy training materials. The dose is extrapolated from allometric scaling of the 10 mcg/kg intraperitoneal dose used in rat studies, adjusted for subcutaneous bioavailability differences 7.

Oral Administration

Some practitioners prescribe oral BPC-157 capsules, typically at 500 mcg once or twice daily. The peptide appears resistant to gastric acid degradation, which is unusual for a peptide of its size. A 2021 study in rats showed oral BPC-157 at 10 mcg/kg produced systemic wound-healing effects comparable to parenteral dosing 8. Whether this gastric stability translates to adequate oral bioavailability in humans is unknown.

Dose Titration

Practitioners who prescribe BPC-157 off-label generally follow a conservative titration approach: start at the lower end of the range (200 mcg/day) for the first 5 to 7 days, assess for injection-site reactions or GI discomfort, and increase to 500 mcg/day only if well tolerated and the clinical response is insufficient.

Safety Profile and Known Risks

BPC-157 has no published human safety data from controlled trials. The safety information below comes from preclinical toxicology, adverse event reports to the FDA, and clinical observation.

Preclinical Toxicology

In rodent studies, BPC-157 showed no organ toxicity at doses up to 100 times the therapeutic range over 30-day exposure periods. LD50 has not been established because no lethal dose was identified in acute toxicity testing 1. Teratogenicity studies have not been conducted.

Reported Side Effects in Clinical Use

Practitioners and patient reports describe a generally mild side-effect profile:

• Common (reported by >5% of users in survey data): Injection-site redness, mild nausea (oral route), transient dizziness
• Uncommon: Headache, fatigue, localized swelling at injection site
• Rare/theoretical: Given BPC-157's pro-angiogenic mechanism, there is a theoretical concern about promoting blood vessel growth in existing tumors. No case reports have confirmed this risk, but patients with active malignancy should avoid BPC-157 until this question is addressed 9.

FDA Regulatory Warnings

The FDA issued multiple warning letters in 2023 and 2024 to compounding pharmacies and online retailers marketing BPC-157 with specific therapeutic claims, including wound healing. The agency noted that BPC-157 is not a component of any FDA-approved drug and that marketing it with disease claims renders it an unapproved new drug 10. This does not prohibit a licensed physician from prescribing BPC-157 through a compounding pharmacy under the physician-patient relationship, but it does mean the product has no regulatory assurance of purity, potency, or sterility beyond the compounding pharmacy's own quality controls.

Who Might Be Considered for BPC-157 (and Who Should Not)

No clinical guideline from any major medical society endorses BPC-157 for wound healing. The following reflects risk-benefit considerations as discussed in regenerative medicine practice.

Potential Candidates

Practitioners most commonly consider BPC-157 for patients who meet all of the following criteria:

• Chronic or slow-healing wounds that have not responded to standard wound care (debridement, moisture management, compression therapy, infection control) for at least 6 to 8 weeks
• No active malignancy or history of malignancy within the past 5 years
• Not pregnant or breastfeeding
• No known hypersensitivity to peptide-based compounds
• Willingness to accept the investigational nature of the therapy and provide informed consent

Absolute Contraindications (Practice-Based)

• Active cancer or pre-malignant conditions (pro-angiogenic mechanism)
• Pregnancy and lactation (no teratogenicity data)
• Patients under 18 years of age
• Known bleeding disorders (BPC-157 interacts with the NO system, which affects platelet function)

How BPC-157 Compares to Standard Wound-Healing Therapies

Standard wound care follows the TIME framework (Tissue management, Infection control, Moisture balance, Edge advancement) endorsed by the Wound Healing Society 11. Evidence-based adjunctive therapies for chronic wounds include negative-pressure wound therapy (NPWT), hyperbaric oxygen, and platelet-rich plasma (PRP). Each of these has at least some human RCT data.

Evidence Comparison

| Therapy | Human RCTs | FDA Cleared/Approved | Typical Cost | |---|---|---|---| | Negative-pressure wound therapy | Multiple (high certainty) | Yes (device clearance) | $100 to $300/week | | Hyperbaric oxygen | Several (moderate certainty) | Yes (for select indications) | $200 to $400/session | | Platelet-rich plasma | Multiple (moderate certainty) | 510(k) cleared kits | $500 to $1,500/treatment | | BPC-157 | None | No | $50 to $150/month (compounded) |

BPC-157's cost is lower than most adjunctive therapies, but the absence of human efficacy data means cost-effectiveness cannot be calculated. A therapy that costs less but does not work is not cost-effective.

Sourcing and Quality Considerations

BPC-157 is obtained through compounding pharmacies in the United States, either 503A (patient-specific prescriptions) or 503B (outsourcing facilities that can produce without patient-specific prescriptions).

What to Verify

• Certificate of Analysis (COA): Should confirm peptide purity of 98% or greater via HPLC
• Sterility testing: For injectable formulations, USP <797> compliance is the minimum standard
• Third-party testing: Some compounding pharmacies submit batches for independent verification; ask for documentation
• Storage requirements: Reconstituted BPC-157 requires refrigeration at 2 to 8°C and should be used within 14 to 28 days depending on the pharmacy's beyond-use dating

The Endocrine Society and the American Association of Clinical Endocrinology (AACE) have both issued position statements urging caution with peptide therapies obtained from non-FDA-regulated sources, noting that contamination, underdosing, and overdosing are documented risks with compounded peptides 12.

Monitoring During BPC-157 Use

Because BPC-157 has no established monitoring guidelines, practitioners who prescribe it typically adapt general peptide-therapy monitoring protocols.

Recommended Baseline and Follow-Up Labs

• Baseline (before starting): CBC with differential, CMP, CRP or ESR (inflammatory markers), wound measurement and photographic documentation
• Week 4: Repeat CRP/ESR, wound measurement, photograph comparison, assessment for injection-site reactions
• Week 8 (end of cycle): Full repeat of baseline labs, wound status assessment, decision to continue or discontinue

Clinical Assessment Points

Wound healing progress should be evaluated using standardized tools such as the Bates-Jensen Wound Assessment Tool (BWAT) or the PUSH (Pressure Ulcer Scale for Healing) score adapted for the wound type 13. A wound that shows less than 30% area reduction at 4 weeks is unlikely to heal with the current treatment plan, a benchmark established in chronic wound literature regardless of therapy 14.

The Regulatory and Ethical Field

BPC-157 occupies a gray zone in U.S. Pharmaceutical regulation. It is not a controlled substance. It is not a dietary supplement (the FDA has rejected this classification). It is not an approved drug.

Informed Consent Requirements

Any physician prescribing BPC-157 off-label should document informed consent that includes: the investigational nature of the peptide, the absence of human efficacy data, the lack of FDA approval for any indication, potential risks including the unknown long-term safety profile, and the availability of evidence-based alternatives.

The American Medical Association's Code of Medical Ethics (Opinion 2.1.5) permits off-label prescribing when "the use is based on sound scientific evidence and sound medical opinion" 15. Whether current BPC-157 evidence meets this threshold is a matter of professional judgment.

Patients with chronic wounds unresponsive to 8 weeks of standard care who are considering BPC-157 should begin with a 200 mcg/day subcutaneous dose, ensure the product comes from a 503B-registered facility with a current COA showing ≥98% purity, and track wound area reduction at 4-week intervals using validated measurement tools.